The Bull Rankings scorecard — our quality-growth score is 72.1 / 100, built from three pillars scored 0–100: Quality 59, Growth 88, Value 73 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 6% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Jazz Pharmaceuticals sits on a growth engine that outpaces its peers, yet the market prices in very little of it. Our model gives it a Quality‑Growth score of 72.1/100, with Growth 88 dwarfing Quality 59. That imbalance tells us the story: the company is a strong grower whose quality is only middling. The price of $245.87 reflects a PE of 16.8 and a PEG of 0.96, while our reverse DCF says the market expects year‑one free‑cash‑flow growth of about ‑6%. That is a stark contrast to the 12.6% revenue growth YoY reported for FY 2026‑06‑30. In other words, the current valuation assumes shrinking cash flow, a pessimistic view that ignores the recent revenue acceleration.
If the company can sustain its 12.6% revenue growth and translate it into free cash flow, the stock is undervalued. The middling Quality pillar is the main drag. The model’s Diluting shareholders signal warns that the share count has been growing, eroding each holder’s stake. Still, the growth narrative is the stronger part of the story.
What the business actually is
Jazz’s revenue engine is anchored in four therapeutic areas: narcolepsy and hypersomnia, epilepsy, hematology, and oncology. The flagship product Xywav treats cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia, while Epidiolex addresses seizures in Lennox‑Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. In oncology, Zepzelca targets metastatic small cell lung cancer after platinum therapy, and Ziihera treats HER2‑positive biliary tract cancer. The hematology line, Rylaze and Enrylaze, treats acute lymphoblastic leukemia and lymphoblastic lymphoma. These products cover niche, high‑need markets with limited competition, creating a steady revenue stream that has grown 12.6% YoY.
Why it can (or can't) keep compounding
Margins remain healthy at 20.4% profit margin and 19.6% ROE, indicating efficient capital use. The company’s debt‑to‑equity ratio of 0.92 is modest, giving it room to invest in R&D or acquisitions. The beta of 0.36 means the stock has moved far less than the market.
The moat lies in the patent protection and regulatory exclusivity of its specialty drugs. For instance, Xywav and Epidiolex occupy narrow therapeutic niches with few alternatives, and their approval pathways are tightly controlled. Competitors cannot replicate these products quickly without significant investment in clinical trials and regulatory approval. The Diluting shareholders signal, however, shows the share count has been rising, which chips away at per‑share gains.
The valuation question
At $245.87, the stock trades at a PE of 16.8 and a PEG of 0.96, a multiple roughly in line with the earnings growth analysts expect. Our reverse‑DCF shows that the current price implies ‑6% free‑cash‑flow growth (in year one, recovering toward 3% a year by year ten)—far below the 12.6% revenue growth reported. The FCF of $1.6b indicates that the company is generating cash, but the implied negative growth suggests the market is pricing in a slowdown. The analyst consensus 1‑year target of $290.6 and a range of $225–$337 reflect analysts’ optimism, well above what the price implies. If Jazz can maintain its revenue trajectory and convert it into cash flow, the stock is trading at a discount to intrinsic value.
The bear case
The most potent skeptic points to the weakest pillar—Quality 59. A middling quality score reflects uneven returns on capital. If the company fails to protect its patents or if a generic entrant emerges, revenue growth could stall. The Diluting shareholders signal is a concrete warning: if the share count keeps rising, it will dilute existing shareholders and erode earnings per share. A concrete trigger would be a debt‑to‑equity rise above 1.0 or a profit margin drop below 15%.
What would change our mind
- Revenue growth dips below 10% YoY: A sustained slowdown would undermine the growth narrative and make the gloomy reverse‑DCF read look more reasonable.
- Profit margin falls below 15%: This would erode the company’s ability to convert sales into cash, weakening the moat and raising concerns about cost control.
- Debt‑to‑equity climbs above 1.0: A higher leverage ratio would signal financial strain and increase the risk of dilution or debt restructuring, eroding shareholder value.
If any of these thresholds are breached, the current bullish thesis would need to be revisited.